Proactiveinvestors recommends
Additional Information
Market: ASX
Sector: Pharmaceuticals
EPIC: SPL
Latest Price: 1.35  (-2.88% Descending)
52-week High: 1.66
52-week Low: 0.96
Market Cap: 334.84M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Starpharma
www.starpharma.com

Starpharma is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications.  The lead pharmaceutical development product is VivaGel®, a vaginal microbicide designed to prevent the transmission of HIV and genital herpes.  Starpharma is developing a VivaGel®-coated condom under a licence agreement with SSL International plc (LSE:SSL), manufacturer of Durex®, the market-leading condom brand worldwide.  Products based on Starpharma’s technology are on the market as diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.  Starpharma is exploring dendrimer opportunities in materials science applications including water remediation and animal health products.

Full Starpharma profile here
Pdf

Orbis Investment Management acquires 2.6m shares in Starpharma Holdings

18th Jun 2010, 12:06 pm

Substantial shareholder Orbis Investment Management has significantly increased its investment in Australian-listed biotechnology company, Starpharma Holdings (ASX:SPL, OTCQX:SPHRY) with the acquisition of 2,564,237 SPL shares on-market at an average price of $0.64 per share between 21 May to 16 June. 

Orbis lodged the change in interests of substantial holder and now owns 20,809,309 shares or 8.71% of Starpharma.

Starpharma is a market leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Its partnerships include Durex, Lilly, Elanco, Stiefel (now GSK), Siemens and Merck. Commencement of royalty revenue is estimated to commence in CY11 with VivaGel coated condoms.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.